RAMPs as drug targets

Advances in Experimental Medicine and Biology

Volumn 744, Issue , 2012, Pages 61-74

  Sexton, Patrick M ^a   Poyner, David R ^b   Simms, John ^a   Christopoulos, Arthur ^a   Hay, Debbie L ^c  

^a MONASH UNIVERSITY   (Australia)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN RECEPTOR; ANTIBODY; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR LIKE RECEPTOR; G PROTEIN COUPLED RECEPTOR; N ETHYLMALEIMIDE SENSITIVE FACTOR; OLCEGEPANT; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RECEPTOR 2; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; TELCAGEPANT;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SURFACE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; G PROTEIN COUPLED RECEPTOR 2 GENE; G PROTEIN COUPLED RECEPTOR GENE; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HEADACHE; HUMAN; INTERNALIZATION; MIGRAINE; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

RECEPTOR ACTIVITY-MODIFYING PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84859791351     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-2364-5_6     Document Type: Article

References (53)

1. Ellis C. The state of GPCR research in 2004. Nat Rev Drug Discov 2004; 3:577-626.
2. McLatchie LM, Fraser NJ, Main MJ et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393:333-339. (Pubitemid 28269699)
3. Christopoulos A, Christopoulos C, Morfis M et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 2003; 278:3293-3297. (Pubitemid 36801242)
4. Fraser NJ, Wise A, Brown J et al. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 1999; 55:1054-1059. (Pubitemid 29252372)
5. Hay DL, Howitt SG, Conner AC et al. CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: A comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS. Br J Pharmacol 2003; 140:477-486. (Pubitemid 37330492)
6. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther 2006; 109:173-197. (Pubitemid 41740820)
7. Poyner DR, Sexton PM, Marshall I et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54:233-246. (Pubitemid 34575714)
8. Christopoulos G, Perry K, Morfis M et al. Multiple amylin receptors arise from receptor-activity-modifying-proteins interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 56:235-242. (Pubitemid 29309833)
9. Muff R, Buhlmann N, Fischer AH et al. An amylin receptor is revealed following cotransfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 1999; 140:2924-2927. (Pubitemid 32245175)
10. Bouschet T, Maritn S, Henley JM et al. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci 2005; 118:4709-4720. (Pubitemid 41646381)
11. Udawela M, et al. The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Seminars Cell Developmental Biol 2004; 15:299-308. (Pubitemid 38581998)
12. Sexton PM, Albiston A, Morfis M et al. Receptor activity modifying proteins. Cellular Signal 2001; 13:73-83. (Pubitemid 32222976)
13. Takei Y, Inoue K, Ogoshi M et al. Identification of novel adrenomedullin in mammals: A potent cardiovascular and renal regulator. FEBS Letters 2004; 556:53-58. (Pubitemid 38058554)
14. Roh J, Chang CL, Bhalla A et al. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004; 279:7264-7274. (Pubitemid 38248876)
15. Hay DL, Christopoulos G, Christopoulos A et al. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl] carbonyl]pentyl]amino]-1-[(3,5- dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4- (1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 2006; 70:1984-1991. (Pubitemid 44771914)
16. Zumpe ET, Tilakaratne N, Fraser NJ et al. Multiple RAMP domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem Biophys Res Commun 2000; 267:368-372. (Pubitemid 30072558)
17. Fitzsimmons TJ, Zhao X, Wank SA. The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function. J Biol Chem 2003; 278:14313-14320. (Pubitemid 36799981)
18. Udawela M, Christopoulos G, Tilakaratne N et al. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol Pharmacol 2006; 69:1984-1989. (Pubitemid 43894317)
19. Steiner S, Muff R, Gujer R et al. The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry 2002; 41:11398-11404.
20. Qi T, Christopoulos G, Bailey RJ et al. Identification of N-terminal receptor activity-modifying protein residues important for CGRP, adrenomedullin and amylin receptor function. Mol Pharmacol 2008; 74:1059-1071.
21. Tilakaratne N, Christopoulos G, Zumpe ET et al. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000; 294:61-72. (Pubitemid 30434671)
22. Moore EE, Kuestner RE, Stroop SD et al. Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrinol 1995; 9:959-968.
23. Udawela M, Christopoulos G, Morfis M et al. A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol Pharmacol 2006; 70:1750-1760.
24. Morfis M, Tilakaratne N, Furness SG et al. Receptor activity modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 2008; 149:5423-5431.
25. Prado MA, Evans-Bain B, Oliver KR et al. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides 2001; 22:1773-1781. (Pubitemid 34062794)
26. Kuwasako K, Shimekake Y, Masuda M et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and Recycling. J Biol Chem 2000; 275:29602-29609. (Pubitemid 32043838)
27. Kuwasako K, Cao YN, Chu CP et al. Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 2006; 281:7205-7213. (Pubitemid 43847487)
28. Bomberger JM, Parameswaran N, Hall CS et al. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J Biol Chem 2005; 280:9297-9307. (Pubitemid 40409622)
29. Phelps E, Bezouglaia O, Tetradis S et al. Parathyroid hormone induces receptor Activity modifying protein-3 (RAMP3) expression primarily via 3',5'-cyclic adenosine monophosphate signaling in osteoblasts. Calcified Tissue International 2005; 77:96-103. (Pubitemid 41507197)
30. Yue W, Dacic S, Sun Q et al. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 2007; 13:4336-4344.
31. Dackor R, Fritz-Six KL, Smithies O et al. Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J Biol Chem 2007; 282:18094-18099. (Pubitemid 47100252)
32. Fritz-Six KL, Dunworth WP, Li M et al. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008; 118:40-50.
33. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008; 118:29-39.
34. Tsujikawa K, Yayama K, Hayashi T et al. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc Natl Acad Sci USA 2007; 104:16702-16707. (Pubitemid 350211080)
35. Zhang Z, Winborn CS, Marquez de Prado B et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 2007; 27:2693-2703. (Pubitemid 46393588)
36. Tam CW, Husmann K, Clark NC et al. Enhanced vascular responses to adrenomedullin in mice overexpressing receptor-activity-modifying protein 2. Circ Res 2006; 98:262-270.
37. Zhao Y, Bell D, Smith LR et al. Differential Expression of Components of the Cardiomyocyte Adrenomedullin/Intermedin Receptor System following Blood Pressure Reduction in Nitric Oxide-Deficient Hypertension. J Pharmacol Exp Ther 2006; 316:1269-1281. (Pubitemid 43345303)
38. Pidasheva S, Canaff L, Simonds WF et al. Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia. Hum Mol Genet 2005; 14:1679-1690. (Pubitemid 40895520)
39. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends Pharmacological Sci 2007; 28:382-389. (Pubitemid 47087967)
40. Kusano S, Kukimoto-Niino M, Akasaka R et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci 2008; 17:1907-1914.
41. Simms J, Hay DL, Wheatley M et al. Characterization of the structure of RAMP1 by mutagenesis and molecular modelling. Biophys J 2006; 91:662-669.
42. ter Haar E, Koth CM, Abdul-Manan N et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 2010; 18:1083-1093.
43. Salvatore CA, Hershey JC, Corcoran HA et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324:416-421. (Pubitemid 351185864)
44. Mallee JJ, Salvatore CA, LeBourdelles B et al. Receptor activity-modifying protein 1 determines the species selectivity of nonpeptide CGRP receptor antagonists. J Biol Chem 2002; 277:14294-14298. (Pubitemid 34968045)
45. Doods H, Hallermayer G, Wu D et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129:420-423. (Pubitemid 30083862)
46. Doods H, Arndt K, Rudolf K et al. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacological Sci 2007; 28:580-587. (Pubitemid 350026615)
47. Ho TW, Ferrari MD, Docick DW et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. The Lancet 2008; 372:2115-2123.
48. Benemei S, Nicoletti P, Capone JA et al. Pain pharmacology in migraine: Focus on CGRP and CGRP receptors. Neurological Sci 2007; 28:S89-S93. (Pubitemid 46813633)
49. Hay DL, Howitt SG, Conner AC et al. A comparison of the actions of BIBN4096BS and CGRP8-37 on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol 2002; 137: 80-86. (Pubitemid 34983466)
50. Salvatore CA, Mallee JJ, Bell IM et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006; 45:1881-1887. (Pubitemid 43222131)
51. Pioszak AA, Xu HE. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci USA 2008; 105:5034-5039. (Pubitemid 351738505)
52. Heroux M, Hogue M, Lemieux S et al. Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J Biol Chem 2007; 282:31610-31620. (Pubitemid 350044900)
53. Kunz TH, Mueller-Steiner S, Schwerdtfeger K et al. Interaction of receptor-activity-modifying protein1 with tubulin. Biochimica et Biophysica Acta (BBA)-General Subjects 2007; 1770:1145-1150. (Pubitemid 47002143)